{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:00:11Z","timestamp":1792602011142,"version":"4.5.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19H05649"],"award-info":[{"award-number":["19H05649"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["19K16512"],"award-info":[{"award-number":["19K16512"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2025,11,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      The development and clinical success of KRAS\n                      <jats:sup>G12C<\/jats:sup>\n                      inhibitors was a landmark achievement in anti-cancer drug development, as oncogenic KRAS had long been considered an intractable therapeutic target. Patients with\n                      <jats:italic>KRAS<\/jats:italic>\n                      mutant lung cancers frequently present with co-mutations in the KEAP1-NRF2 pathway, and because genetic activation of NRF2 results in resistance to all current anti-cancer therapies, we were motivated to explore how aberrant activation of NRF2 impacts the clinical response to KRAS\n                      <jats:sup>G12C<\/jats:sup>\n                      inhibitors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A broad range of techniques, including genetic knockouts, scRNA-seq and surface plasmon resonance, were used to determine the effect of KRAS\n                      <jats:sup>G12C<\/jats:sup>\n                      drugs on NRF2.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      At physiologically-relevant concentrations, both of the clinically-approved KRAS\n                      <jats:sup>G12C<\/jats:sup>\n                      inhibitors Sotorasib and Adagrasib also function as inducers of NRF2. Mechanistically, the same cysteine-targeting functionality which allows these electrophilic drugs to inhibit the mutant KRAS\n                      <jats:sup>G12C<\/jats:sup>\n                      protein also facilitates their binding to cysteine-based sensors in KEAP1, resulting in the upregulation of the NRF2-dependent gene expression program.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The activation of NRF2 by KRAS-G12C inhibitors represents a unique example of anti-cancer drugs which positively regulate the activity of a protein which is normally considered to be an oncogene. In both the malignant cells of the tumour and immune cells within the microenvironment, activation of NRF2 by electrophilic KRAS inhibitors positively contributes to the clinical efficacy of these drugs by promoting anti-cancer immunity. This unprecedented situation, in which the NRF2-dependent oxidative stress response is induced globally within cancer patients, has a number of important clinical implications, particularly in relation to ongoing combination chemotherapy clinical trials, as well as for selecting patient populations which may derive the most benefit from G12Ci anti-cancer drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41416-025-03162-7","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T09:37:14Z","timestamp":1756719434000},"page":"1377-1390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Systemic activation of NRF2 contributes to the therapeutic efficacy of clinically-approved KRAS-G12C anti-cancer drugs"],"prefix":"10.1038","volume":"133","author":[{"given":"Liam","family":"Baird","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyu","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Tateno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuro","family":"Iso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2970-7742","authenticated-orcid":false,"given":"Kazuki","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fumiki","family":"Katsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9073-9436","authenticated-orcid":false,"given":"Masayuki","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"3162_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74:12\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3162_CR2","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","volume":"173","author":"F Sanchez-Vega","year":"2018","unstructured":"Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, et al. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell. 2018;173:321\u201337.e10.","journal-title":"Cell"},{"key":"3162_CR3","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41591-024-02903-0","volume":"30","author":"A Singhal","year":"2024","unstructured":"Singhal A, Li BT, O\u2019Reilly EM. Targeting KRAS in cancer. Nat Med. 2024;30:969\u201383.","journal-title":"Nat Med"},{"key":"3162_CR4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","volume":"24","author":"N Perurena","year":"2024","unstructured":"Perurena N, Situ L, Cichowski K. Combinatorial strategies to target RAS-driven cancers. Nat Rev Cancer. 2024;24:316\u201337.","journal-title":"Nat Rev Cancer"},{"key":"3162_CR5","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1039\/D0MD00096E","volume":"11","author":"L Goebel","year":"2020","unstructured":"Goebel L, M\u00fcller MP, Goody RS, Rauh D. KRasG12C inhibitors in clinical trials: a short historical perspective. RSC Med Chem. 2020;11:760\u201370.","journal-title":"RSC Med Chem"},{"key":"3162_CR6","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nature12796","volume":"503","author":"JM Ostrem","year":"2013","unstructured":"Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature. 2013;503:548\u201351.","journal-title":"Nature"},{"key":"3162_CR7","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1158\/2159-8290.CD-15-1105","volume":"6","author":"MP Patricelli","year":"2016","unstructured":"Patricelli MP, Janes MR, Li LS, Hansen R, Peters U, Kessler LV, et al. Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State. Cancer Discov. 2016;6:316\u201329.","journal-title":"Cancer Discov"},{"key":"3162_CR8","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.cell.2018.01.006","volume":"172","author":"MR Janes","year":"2018","unstructured":"Janes MR, Zhang J, Li LS, Hansen R, Peters U, Guo X, et al. Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor. Cell. 2018;172:578\u201389.e17.","journal-title":"Cell"},{"key":"3162_CR9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","volume":"575","author":"J Canon","year":"2019","unstructured":"Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575:217\u201323.","journal-title":"Nature"},{"key":"3162_CR10","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa1917239","volume":"383","author":"DS Hong","year":"2020","unstructured":"Hong DS, Fakih MG, Strickler JH, Desai J, Durn GA, Shapiro GI, et al. KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. N. Engl J Med. 2020;383:1207\u201317.","journal-title":"N. Engl J Med"},{"key":"3162_CR11","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis F, Li BT, Dy GK, Price TJ, Falchook GS, Wolf J, et al. Sotorasib for Lung Cancers with KRAS p.G12C Mutation. N. Engl J Med. 2021;384:2371\u201381.","journal-title":"N. Engl J Med"},{"key":"3162_CR12","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1158\/1078-0432.CCR-21-3074","volume":"28","author":"EC Nakajima","year":"2022","unstructured":"Nakajima EC, Drezner N, Li X, Mishra-Kalyani PS, Liu Y, Zhao H, et al. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC. Clin Cancer Res. 2022;28:1482\u20136.","journal-title":"Clin Cancer Res"},{"key":"3162_CR13","volume":"10","author":"SA Best","year":"2019","unstructured":"Best SA, Ding S, Kersbergen A, Dong X, Song JY, Xie Y, et al. Distinct initiating events underpin the immune and metabolic heterogeneity of KRAS-mutant lung adenocarcinoma. Nat Commun. 2019;10:4190.","journal-title":"Nat Commun"},{"key":"3162_CR14","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1006\/bbrc.1997.6943","volume":"236","author":"K Itoh","year":"1997","unstructured":"Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2\/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997;236:313\u201322.","journal-title":"Biochem Biophys Res Commun"},{"key":"3162_CR15","doi-asserted-by":"crossref","first-page":"15259","DOI":"10.1073\/pnas.1305687110","volume":"110","author":"L Baird","year":"2013","unstructured":"Baird L, Ll\u00e8res D, Swift S, Dinkova-Kostova AT. Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc Natl Acad Sci USA. 2013;110:15259\u201364.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3162_CR16","doi-asserted-by":"crossref","first-page":"102904","DOI":"10.1016\/j.redox.2023.102904","volume":"67","author":"L Baird","year":"2023","unstructured":"Baird L, Yamamoto M. Immunoediting of KEAP1-NRF2 mutant tumours is required to circumvent NRF2-mediated immune surveillance. Redox Biol. 2023;67:102904.","journal-title":"Redox Biol"},{"key":"3162_CR17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.freeradbiomed.2022.05.017","volume":"187","author":"H Panda","year":"2022","unstructured":"Panda H, Suzuki M, Naito M, Saito R, Wen H, Baird L, et al. Halofuginone micelle nanoparticles eradicate Nrf2-activated lung adenocarcinoma without systemic toxicity. Free Radic Biol Med. 2022;187:92\u2013104.","journal-title":"Free Radic Biol Med"},{"key":"3162_CR18","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2767-9764.CRC-23-0386","volume":"4","author":"SH Hamad","year":"2024","unstructured":"Hamad SH, Sellers RS, Wamsley N, Zolkind P, Schrank TP, Major MB, et al. NRF2 Activation in Trp53;p16-deficient Mice Drives Oral Squamous Cell Carcinoma. Cancer Res Commun. 2024;4:487\u201395.","journal-title":"Cancer Res Commun"},{"key":"3162_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1080\/10985549.2024.2438817","volume":"45","author":"H Oshikiri","year":"2025","unstructured":"Oshikiri H, Taguchi K, Hirose W, Taniyama Y, Kamei T, Siegel D, et al. Anticancer Effect of C19-Position Substituted Geldanamycin Derivatives Targeting NRF2-NQO1-activated Esophageal Squamous Cell Carcinoma. Mol Cell Biol. 2025;45:79\u201397.","journal-title":"Mol Cell Biol"},{"key":"3162_CR20","first-page":"15","volume":"51","author":"S Shalapour","year":"2019","unstructured":"Shalapour S, Karin M. Pas de Deux: Control of Anti-tumor. Immun Cancer-Associated Inflamm Immun. 2019;51:15\u201326.","journal-title":"Immun Cancer-Associated Inflamm Immun"},{"key":"3162_CR21","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/s41556-022-01002-x","volume":"24","author":"KC Kao","year":"2022","unstructured":"Kao KC, Vilbois S, Tsai CH, Ho PC. Metabolic communication in the tumour-immune microenvironment. Nat Cell Biol. 2022;24:1574\u201383.","journal-title":"Nat Cell Biol"},{"key":"3162_CR22","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1002\/eji.1830260620","volume":"26","author":"K Kono","year":"1996","unstructured":"Kono K, Salazar-Onfray F, Petersson M, Hansson J, Masucci G, Wasserman K, et al. Hydrogen peroxide secreted by tumor-derived macrophages down-modulates signal-transducing zeta molecules and inhibits tumor-specific T cell-and natural killer cell-mediated cytotoxicity. Eur J Immunol. 1996;26:1308\u201313.","journal-title":"Eur J Immunol"},{"key":"3162_CR23","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/s41590-020-0725-2","volume":"21","author":"SA Vardhana","year":"2020","unstructured":"Vardhana SA, Hwee MA, Berisa M, Wells DK, Yost KE, King B, et al. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T cells exposed to persistent antigen. Nat Immunol. 2020;21:1022\u201333.","journal-title":"Nat Immunol"},{"key":"3162_CR24","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.4049\/jimmunol.167.5.2595","volume":"167","author":"KJ Malmberg","year":"2001","unstructured":"Malmberg KJ, Arulampalam V, Ichihara F, Petersson M, Seki K, Andersson T, et al. Inhibition of activated\/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol. 2001;167:2595\u2013601.","journal-title":"J Immunol"},{"key":"3162_CR25","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.4049\/jimmunol.174.10.6080","volume":"174","author":"A Takahashi","year":"2005","unstructured":"Takahashi A, Hanson MGV, Norell HR, Havelka AM, Kono K, Malmberg KJ, et al. Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress. J Immunol. 2005;174:6080\u20137.","journal-title":"J Immunol"},{"key":"3162_CR26","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","volume":"10","author":"RA Flavell","year":"2010","unstructured":"Flavell RA, Sanjabi S, Wrzesinski SH, Licona-Lim\u00f3n P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol. 2010;10:554\u201367.","journal-title":"Nat Rev Immunol"},{"key":"3162_CR27","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ccell.2014.09.006","volume":"26","author":"B Ruffell","year":"2014","unstructured":"Ruffell B, Chang-Strachan D, Chan V, Rosenbusch A, Ho CMT, Pryer N, et al. Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. Cancer Cell. 2014;26:623\u201337.","journal-title":"Cancer Cell"},{"key":"3162_CR28","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","volume":"23","author":"L Cassetta","year":"2023","unstructured":"Cassetta L, Pollard JW. A timeline of tumour-associated macrophage biology. Nat Rev Cancer. 2023;23:238\u201357.","journal-title":"Nat Rev Cancer"},{"key":"3162_CR29","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41590-019-0512-0","volume":"20","author":"LP Andrews","year":"2019","unstructured":"Andrews LP, Yano H, Vignali DAA. Inhibitory receptors and ligands beyond PD-1, PD-L1 and CTLA-4: breakthroughs or backups. Nat Immunol. 2019;20:1425\u201334.","journal-title":"Nat Immunol"},{"key":"3162_CR30","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/nature19834","volume":"539","author":"MM Kaneda","year":"2016","unstructured":"Kaneda MM, Messer KS, Ralainirina N, Li H, Leem CJ, Gorjestani S, et al. PI3K\u03b3 is a molecular switch that controls immune suppression. Nature. 2016;539:437\u201342.","journal-title":"Nature"},{"key":"3162_CR31","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41568-022-00546-2","volume":"23","author":"ST Barry","year":"2023","unstructured":"Barry ST, Gabrilovich DI, Sansom OJ, Campbell AD, Morton JP. Therapeutic targeting of tumour myeloid cells. Nat Rev Cancer. 2023;23:216\u201337.","journal-title":"Nat Rev Cancer"},{"key":"3162_CR32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/iub.2680","volume":"74","author":"L Baird","year":"2022","unstructured":"Baird L, Kensler TW, Yamamoto M. Novel NRF2-activated cancer treatments utilizing synthetic lethality. IUBMB Life. 2022;74:1209\u201331.","journal-title":"IUBMB Life"},{"key":"3162_CR33","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/s41580-024-00730-2","volume":"25","author":"H Sies","year":"2024","unstructured":"Sies H, Mailloux RJ, Jakob U. Fundamentals of redox regulation in biology. Nat Rev Mol Cell Biol. 2024;25:701\u201319.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3162_CR34","first-page":"e00377","volume":"40","author":"L Baird","year":"2020","unstructured":"Baird L, Suzuki T, Takahashi Y, Hishinuma E, Saigusa D, Yamamoto M. Geldanamycin-Derived HSP90 Inhibitors Are Synthetic Lethal with NRF2. Mol Cell Biol. 2020;40:e00377\u201320.","journal-title":"Mol Cell Biol"},{"key":"3162_CR35","doi-asserted-by":"crossref","first-page":"8261","DOI":"10.1073\/pnas.85.21.8261","volume":"85","author":"P Talalay","year":"1988","unstructured":"Talalay P, De Long MJ, Prochaska HJ. Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis. Proc Natl Acad Sci USA. 1988;85:8261\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3162_CR36","doi-asserted-by":"crossref","first-page":"200105","DOI":"10.1098\/rsob.200105","volume":"10","author":"S Dayalan Naidu","year":"2020","unstructured":"Dayalan Naidu S, Dinkova-Kostova AT. KEAP1, a cysteine-based sensor and a drug target for the prevention and treatment of chronic disease. Open Biol. 2020;10:200105.","journal-title":"Open Biol"},{"key":"3162_CR37","doi-asserted-by":"crossref","first-page":"6679","DOI":"10.1021\/acs.jmedchem.9b02052","volume":"63","author":"JB Fell","year":"2020","unstructured":"Fell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, et al. Identification of the Clinical Development Candidate MRTX849, a Covalent KRASG12C Inhibitor for the Treatment of Cancer. J Med Chem. 2020;63:6679\u201393.","journal-title":"J Med Chem"},{"key":"3162_CR38","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SHI, Pacheco JM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N. Engl J Med. 2022;387:120\u201331.","journal-title":"N. Engl J Med"},{"key":"3162_CR39","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tifs.2017.02.002","volume":"69","author":"AT Dinkova-Kostova","year":"2017","unstructured":"Dinkova-Kostova AT, Fahey JW, Kostov RV, Kensler TWKEAP1. and Done? Targeting the NRF2 Pathway with Sulforaphane. Trends Food Sci Technol. 2017;69:257\u201369.","journal-title":"Trends Food Sci Technol"},{"key":"3162_CR40","doi-asserted-by":"crossref","first-page":"eabm8780","DOI":"10.1126\/sciadv.abm8780","volume":"8","author":"E Mugarza","year":"2022","unstructured":"Mugarza E, van Maldegem F, Boumelha J, Moore C, Rana S, Sopena ML, et al. Therapeutic KRASG12C inhibition drives effective interferon-mediated antitumor immunity in immunogenic lung cancers. Sci Adv. 2022;8:eabm8780.","journal-title":"Sci Adv"},{"key":"3162_CR41","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1038\/s41591-022-02007-7","volume":"28","author":"J Hallin","year":"2022","unstructured":"Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, et al. Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor. Nat Med. 2022;28:2171\u201382.","journal-title":"Nat Med"},{"key":"3162_CR42","first-page":"553","volume":"16","author":"SL Tammaccaro","year":"2023","unstructured":"Tammaccaro SL, Progent P, Le Bail JC, Dos-Santos O, Dassencourt L, Eskandar M, et al. TEAD Inhibitors Sensitize KRASG12C Inhibitors via Dual Cell Cycle Arrest in KRASG12C-Mutant NSCLC. Pharm (Basel). 2023;16:553.","journal-title":"Pharm (Basel)"},{"key":"3162_CR43","doi-asserted-by":"crossref","first-page":"e155523","DOI":"10.1172\/JCI155523","volume":"132","author":"YS Tsai","year":"2022","unstructured":"Tsai YS, Woodcock MG, Azam SH, Thorne LB, Kanchi KL, Parker JS, et al. Rapid idiosyncratic mechanisms of clinical resistance to KRAS G12C inhibition. J Clin Invest. 2022;132:e155523.","journal-title":"J Clin Invest"},{"key":"3162_CR44","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1128\/MCB.00868-15","volume":"36","author":"R Saito","year":"2016","unstructured":"Saito R, Suzuki T, Hiramoto K, Asami S, Naganuma E, Suda H, et al. Characterizations of Three Major Cysteine Sensors of Keap1 in Stress Response. Mol Cell Biol. 2016;36:271\u201384.","journal-title":"Mol Cell Biol"},{"key":"3162_CR45","doi-asserted-by":"crossref","unstructured":"Baird L & Yamamoto M. \u201cThe Keap1-Nrf2 pathway: From mechanism to medical applications.\u201d Oxidative Stress, edited by Helmut Sies. pp. 125-147. Academic Press, 2020.","DOI":"10.1016\/B978-0-12-818606-0.00009-2"},{"key":"3162_CR46","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41591-023-02717-6","volume":"30","author":"Y Kuboki","year":"2024","unstructured":"Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, et al. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024;30:265\u201370.","journal-title":"Nat Med"},{"key":"3162_CR47","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1158\/1535-7163.MCT-20-0462","volume":"20","author":"DM Briere","year":"2021","unstructured":"Briere DM, Li S, Calinisan N, Aranda R, Hargis L, Peng DH, et al. The KRASG12C Inhibitor MRTX849 Reconditions the Tumor Immune Microenvironment and Sensitizes Tumors to Checkpoint Inhibitor Therapy. Mol Cancer Ther. 2021;20:975\u201385.","journal-title":"Mol Cancer Ther"},{"key":"3162_CR48","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26214-x","volume":"12","author":"F van Maldegem","year":"2021","unstructured":"van Maldegem F, Valand K, Cole M, Patel H, Angelova M, Rana S, et al. Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. Nat Commun. 2021;12:5906.","journal-title":"Nat Commun"},{"key":"3162_CR49","doi-asserted-by":"crossref","first-page":"113911","DOI":"10.1016\/j.ejca.2024.113911","volume":"201","author":"JA Stratmann","year":"2024","unstructured":"Stratmann JA, Althoff FC, Doebel P, Rauh J, Trummer A, Hunerliturkoglu AN, et al. Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany. Eur J Cancer. 2024;201:113911.","journal-title":"Eur J Cancer"},{"key":"3162_CR50","doi-asserted-by":"crossref","first-page":"102845","DOI":"10.1016\/j.redox.2023.102845","volume":"66","author":"L Baird","year":"2023","unstructured":"Baird L, Taguchi K, Zhang A, Takahashi Y, Suzuki T, Kensler TW, et al. A NRF2-induced secretory phenotype activates immune surveillance to remove irreparably damaged cells. Redox Biol. 2023;66:102845.","journal-title":"Redox Biol"},{"key":"3162_CR51","doi-asserted-by":"crossref","first-page":"1094123","DOI":"10.3389\/fonc.2023.1094123","volume":"13","author":"DJ Sisler","year":"2023","unstructured":"Sisler DJ, Hinz TK, Le AT, Kleczko EK, Nemenoff RA, Heasley LE. Evaluation of KRASG12C inhibitor responses in novel murine KRASG12C lung cancer cell line models. Front Oncol. 2023;13:1094123.","journal-title":"Front Oncol"},{"key":"3162_CR52","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.ccell.2024.02.012","volume":"42","author":"M Molina-Arcas","year":"2024","unstructured":"Molina-Arcas M, Downward J. Exploiting the therapeutic implications of KRAS inhibition on tumor immunity. Cancer Cell. 2024;42:338\u201357.","journal-title":"Cancer Cell"},{"key":"3162_CR53","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1093\/carcin\/bgn095","volume":"29","author":"XJ Wang","year":"2008","unstructured":"Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, Li Y, et al. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis. 2008;29:1235\u201343.","journal-title":"Carcinogenesis"},{"key":"3162_CR54","doi-asserted-by":"crossref","first-page":"e00473","DOI":"10.1128\/MCB.00473-20","volume":"41","author":"L Baird","year":"2021","unstructured":"Baird L, Yamamoto M. NRF2-Dependent Bioactivation of Mitomycin C as a Novel Strategy To Target KEAP1-NRF2 Pathway Activation in Human Cancer. Mol Cell Biol. 2021;41:e00473\u201320.","journal-title":"Mol Cell Biol"},{"key":"3162_CR55","doi-asserted-by":"crossref","first-page":"209ra153","DOI":"10.1126\/scitranslmed.3006802","volume":"5","author":"Clinical Lung Cancer Genome Project (CLCGP)Network Genomic Medicine (NGM).","year":"2013","unstructured":"Clinical Lung Cancer Genome Project (CLCGP) & Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med. 2013;5:209ra153.","journal-title":"Sci Transl Med"},{"key":"3162_CR56","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1158\/2159-8290.CD-22-1420","volume":"13","author":"MV Negrao","year":"2023","unstructured":"Negrao MV, Araujo HA, Lamberti G, Cooper AJ, Akhave NS, Zhou T, et al. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023;13:1556\u201371.","journal-title":"Cancer Discov"},{"key":"3162_CR57","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41586-021-04065-2","volume":"599","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, et al. Diverse alterations associated with resistance to KRAS(G12C) inhibition. Nature. 2021;599:679\u201383.","journal-title":"Nature"},{"key":"3162_CR58","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41568-021-00435-0","volume":"22","author":"EC Cheung","year":"2022","unstructured":"Cheung EC, Vousden KH. The role of ROS in tumour development and progression. Nat Rev Cancer. 2022;22:280\u201397.","journal-title":"Nat Rev Cancer"},{"key":"3162_CR59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.phrs.2015.07.024","volume":"100","author":"M Cao","year":"2015","unstructured":"Cao M, Evans OO, Williams CR, Royce DB, Gribble GW, Sporn MB, et al. Novel synthetic pyridyl analogues of CDDO-Imidazolide are useful new tools in cancer prevention. Pharm Res. 2015;100:135\u201347.","journal-title":"Pharm Res"},{"key":"3162_CR60","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1124\/molpharm.123.000671","volume":"104","author":"T Gatbonton-Schwager","year":"2023","unstructured":"Gatbonton-Schwager T, Yagashita Y, Joshi T, Wakabayashi N, Srinivasan H, Suzuki T, et al. A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me). Mol Pharm. 2023;104:51\u201361.","journal-title":"Mol Pharm"},{"key":"3162_CR61","doi-asserted-by":"crossref","first-page":"106080","DOI":"10.1016\/j.isci.2023.106080","volume":"26","author":"Y Wang","year":"2023","unstructured":"Wang Y, Zhong B, Xu C, Zhan D, Zhao S, Wu H, et al. Global profiling of AMG510 modified proteins identified tumor suppressor KEAP1 as an off-target. iScience. 2023;26:106080.","journal-title":"iScience"},{"key":"3162_CR62","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.chembiol.2023.11.015","volume":"31","author":"K Yang","year":"2024","unstructured":"Yang K, Whitehouse RL, Dawson SL, Zhang L, Martin JG, Johnson DS, et al. Accelerating multiplexed profiling of protein-ligand interactions: High-throughput plate-based reactive cysteine profiling with minimal input. Cell Chem Biol. 2024;31:565\u201376.e4.","journal-title":"Cell Chem Biol"},{"key":"3162_CR63","volume":"7","author":"EH Kobayashi","year":"2016","unstructured":"Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Hayashi M, Sekine H, et al. Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription. Nat Commun. 2016;7:11624.","journal-title":"Nat Commun"},{"key":"3162_CR64","volume":"12","author":"S Jin","year":"2021","unstructured":"Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, et al. Inference and analysis of cell-cell communication using CellChat. Nat Commun. 2021;12:1088.","journal-title":"Nat Commun"},{"key":"3162_CR65","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.immuni.2019.03.020","volume":"50","author":"W Ouyang","year":"2019","unstructured":"Ouyang W, O\u2019Garra A. IL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation. Immunity. 2019;50:871\u201391.","journal-title":"Immunity"},{"key":"3162_CR66","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.freeradbiomed.2025.03.034","volume":"233","author":"K Wang","year":"2025","unstructured":"Wang K, Baird L, Yamamoto M. The clinical-grade CBP\/ p300 inhibitor CCS1477 represses the global NRF2-dependent cytoprotective transcription program and re-sensitizes cancer cells to chemotherapeutic drugs. Free Radic Biol Med. 2025;233:102\u201317.","journal-title":"Free Radic Biol Med"},{"key":"3162_CR67","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1093\/jb\/mvae008","volume":"175","author":"YI Aoki","year":"2024","unstructured":"Aoki YI, Taguchi K, Anzawa H, Kawashima J, Ishida N, Otsuki A, et al. Whole blood transcriptome analysis for age- and gender-specific gene expression profiling in Japanese individuals. J Biochem. 2024;175:611\u201327.","journal-title":"J Biochem"},{"key":"3162_CR68","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1056\/NEJMoa2308795","volume":"389","author":"MG Fakih","year":"2023","unstructured":"Fakih MG, Salvatore L, Esaki T, Modest DP, Lopez-Bravo DP, Taieb J, et al. Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C. N. Engl J Med. 2023;389:2125\u201339.","journal-title":"N. Engl J Med"},{"key":"3162_CR69","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/s41591-021-01450-2","volume":"27","author":"M Wang","year":"2021","unstructured":"Wang M, Herbst RS, Boshoff C. Toward personalized treatment approaches for non-small-cell lung cancer. Nat Med. 2021;27:1345\u201356.","journal-title":"Nat Med"},{"key":"3162_CR70","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1084\/jem.20101956","volume":"208","author":"B Molon","year":"2011","unstructured":"Molon B, Ugel S, Del Pozzo F, Soldani C, Zilio S, Avella D, et al. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells. J Exp Med. 2011;208:1949\u201362.","journal-title":"J Exp Med"},{"key":"3162_CR71","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13:828\u201335.","journal-title":"Nat Med"},{"key":"3162_CR72","volume":"8","author":"GXY Zheng","year":"2017","unstructured":"Zheng GXY, Terry JM, Belgrader P, Ryvkin P, Bent ZW, Wilson R, et al. Massively parallel digital transcriptional profiling of single cells. Nat Commun. 2017;8:14049.","journal-title":"Nat Commun"},{"key":"3162_CR73","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis CS, Murrow LM, Gartner ZJ. DoubletFinder: Doublet Detection in Single-Cell RNA Sequencing Data Using Artificial Nearest Neighbors. Cell Syst. 2019;8:329\u201337.e4.","journal-title":"Cell Syst"},{"key":"3162_CR74","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, et al. Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol. 2024;42:293\u2013304.","journal-title":"Nat Biotechnol"},{"key":"3162_CR75","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","volume":"16","author":"I Korsunsky","year":"2019","unstructured":"Korsunsky I, Milard N, Fan J, Slowikowski K, Zhang F, Wei K, et al. Fast, sensitive and accurate integration of single-cell data with Harmony. Nat Methods. 2019;16:1289\u201396.","journal-title":"Nat Methods"},{"key":"3162_CR76","doi-asserted-by":"crossref","unstructured":"Zappia L & Oshlack A. Clustering trees: a visualization for evaluating clusterings at multiple resolutions. Gigascience. 2018;7:,giy083.","DOI":"10.1093\/gigascience\/giy083"},{"key":"3162_CR77","doi-asserted-by":"crossref","DOI":"10.1186\/s13059-019-1676-5","volume":"20","author":"KN Natarajan","year":"2019","unstructured":"Natarajan KN, Miao Z, Jiang M, Huang X, Zhou H, Xie J, et al. Comparative analysis of sequencing technologies for single-cell transcriptomics. Genome Biol. 2019;20:70.","journal-title":"Genome Biol"},{"key":"3162_CR78","first-page":"100141","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov (Camb). 2021;2:100141.","journal-title":"Innov (Camb)"},{"key":"3162_CR79","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1126\/science.aad0501","volume":"352","author":"I Tirosh","year":"2016","unstructured":"Tirosh I, Izar B, Prakadan SM, Wadsworth MH, Treacy D, Trombetta JJ, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. Science. 2016;352:189\u201396.","journal-title":"Science"},{"key":"3162_CR80","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1002\/imt2.107","volume":"2","author":"S Chen","year":"2023","unstructured":"Chen S. Ultrafast one-pass FASTQ data preprocessing, quality control, and deduplication using fastp. Imeta. 2023;2:e107.","journal-title":"Imeta"},{"key":"3162_CR81","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.3317","volume":"12","author":"D Kim","year":"2015","unstructured":"Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12:357\u201360.","journal-title":"Nat Methods"},{"key":"3162_CR82","doi-asserted-by":"crossref","DOI":"10.1093\/gigascience\/giab008","volume":"10","author":"P Danecek","year":"2021","unstructured":"Danecek P, Bonfield JK, Liddle J, Marshall J, Ohan V, Polard MO, et al. Twelve years of SAMtools and BCFtools. Gigascience. 2021;10:giab008.","journal-title":"Gigascience"},{"key":"3162_CR83","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nbt.3122","volume":"33","author":"M Pertea","year":"2015","unstructured":"Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33:290\u20135.","journal-title":"Nat Biotechnol"},{"key":"3162_CR84","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.","journal-title":"Genome Biol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03162-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03162-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03162-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T21:46:49Z","timestamp":1761774409000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-025-03162-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":84,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,11,16]]}},"alternative-id":["3162"],"URL":"https:\/\/doi.org\/10.1038\/s41416-025-03162-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This project was performed as a part of the prospective cohort study at the Tohoku Medical Megabank (TMM), with the approval of the institutional review board (IRB) at Tohoku University. All methods were performed in accordance with the relevant guidelines and regulations from Tohoku University. The human PBMC samples used in this study were from TMM cohort participants, all of whom gave TMM their written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}